Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 4, Avril 2015
Page(s) 377 - 382
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153104011
Publié en ligne 8 mai 2015
  1. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002 ; 418 : 646–650. [CrossRef] [PubMed]
  2. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008 ; 451 : 425–430. [CrossRef] [PubMed]
  3. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys. Nature 2004 ; 427 : 848–853. [CrossRef] [PubMed]
  4. Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011 ; 474 : 658–661. [CrossRef] [PubMed]
  5. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011 ; 474 : 654–657. [CrossRef] [PubMed]
  6. Goujon C, Moncorge O, Bauby H, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013 ; 502 : 559–562. [CrossRef] [PubMed]
  7. Kane M, Yadav SS, Bitzegeio J, et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 2013 ; 502 : 563–566. [CrossRef] [PubMed]
  8. Liu Z, Pan Q, Ding S, et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 2013 ; 14 : 398–410. [CrossRef] [PubMed]
  9. La Goujon C. protéine MX2 humaine est l’un des acteurs de la réponse interféron contre le VIH-1. Med Sci (Paris) 2014 ; 30 : 233–235. [CrossRef] [EDP Sciences] [PubMed]
  10. Brass AL, Huang IC, Benita Y, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009 ; 139 : 1243–1254. [CrossRef] [PubMed]
  11. Lu J, Pan Q, Rong L, et al. The IFITM proteins inhibit HIV-1 infection. J Virol 2011 ; 85 : 2126–2137. [CrossRef] [PubMed]
  12. Weidner JM, Jiang D, Pan XB, et al. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 2010 ; 84 : 12646–12657. [CrossRef] [PubMed]
  13. Anafu AA, Bowen CH, Chin CR, et al. Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. J Biol Chem 2013 ; 288 : 17261–17271. [CrossRef] [PubMed]
  14. Wilkins C, Woodward J, Lau DT, et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 2013 ; 57 : 461–469. [CrossRef] [PubMed]
  15. Mudhasani R, Tran JP, Retterer C, et al. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift valley fever virus. J Virol 2013 ; 87 : 8451–8464. [CrossRef] [PubMed]
  16. Huang IC, Bailey CC, Weyer JL, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 2011 ; 7 : e1001258. [CrossRef] [PubMed]
  17. Warren CJ, Griffin LM, Little AS, et al. The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One 2014 ; 9 : e96579. [CrossRef] [PubMed]
  18. Zhao X, Guo F, Liu F, et al. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci USA 2014 ; 111 : 6756–6761. [CrossRef]
  19. Smith SE, Gibson MS, Wash RS, et al. Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro. J Virol 2013 ; 87 : 12957–12966. [CrossRef] [PubMed]
  20. Hickford D, Frankenberg S, Shaw G, Renfree MB. Evolution of vertebrate interferon inducible transmembrane proteins. BMC Genomics 2012 ; 13 : 155. [CrossRef] [PubMed]
  21. Yount JS, Karssemeijer RA, Hang HC. S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. J Biol Chem 2012 ; 287 : 19631–19641. [CrossRef] [PubMed]
  22. Bailey CC, Kondur HR, Huang IC, Farzan M. Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J Biol Chem 2013 ; 288 : 32184–32193. [CrossRef] [PubMed]
  23. Weston S, Czieso S, White IJ, et al. A membrane topology model for human interferon inducible transmembrane protein 1. PLoS One 2014 ; 9 : e104341. [CrossRef] [PubMed]
  24. John SP, Chin CR, Perreira JM, et al. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol 2013 ; 87 : 7837–7852. [CrossRef] [PubMed]
  25. Jia R, Pan Q, Ding S, et al. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol 2012 ; 86 : 13697–13707. [CrossRef] [PubMed]
  26. Yount JS, Moltedo B, Yang YY, et al. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat Chem Biol 2010 ; 6 : 610–614. [CrossRef] [PubMed]
  27. Shan Z, Han Q, Nie J, et al. Negative regulation of interferon-induced transmembrane protein 3 by SET7-mediated lysine monomethylation. J Biol Chem 2013 ; 288 : 35093–35103. [CrossRef] [PubMed]
  28. Chesarino NM, McMichael TM, Hach JC, Yount JS. Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination. J Biol Chem 2014 ; 289 : 11986–11992. [CrossRef] [PubMed]
  29. Feeley EM, Sims JS, John SP, et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog 2011 ; 7 : e1002337. [CrossRef] [PubMed]
  30. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, et al. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 2013 ; 13 : 452–464. [CrossRef] [PubMed]
  31. Jia R, Xu F, Qian J, et al. Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol 2014 ; 16 : 1080–1093. [CrossRef] [PubMed]
  32. Diamond MS, Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 2013 ; 13 : 46–57. [CrossRef] [PubMed]
  33. Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 2002 ; 20 : 1151–1154. [CrossRef] [PubMed]
  34. Li K, Markosyan RM, Zheng YM, et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog 2013 ; 9 : e1003124. [CrossRef] [PubMed]
  35. Desai TM, Marin M, Chin CR, et al. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog 2014 ; 10 : e1004048. [CrossRef] [PubMed]
  36. Lin TY, Chin CR, Everitt AR, et al. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep 2013 ; 5 : 895–908. [CrossRef] [PubMed]
  37. Chutiwitoonchai N, Hiyoshi M, Hiyoshi-Yoshidomi Y, et al. Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins. Microbes Infect 2013 ; 15 : 280–290. [CrossRef] [PubMed]
  38. Ding S, Pan Q, Liu SL, Liang C. HIV-1 mutates to evade IFITM1 restriction. Virology 2014 ; 454–5 : 11–24. [CrossRef]
  39. Saitou M, Barton SC, Surani MA. A molecular programme for the specification of germ cell fate in mice. Nature 2002 ; 418 : 293–300. [CrossRef] [PubMed]
  40. Hisamatsu T, Watanabe M, Ogata H, et al. Interferon-inducible gene family 1–8U expression in colitis-associated colon cancer and severely inflamed mucosa in ulcerative colitis. Cancer Res 1999 ; 59 : 5927–5931. [PubMed]
  41. Marquet R, Guerreri S, Bernacchi S, et al. Un facteur de transcription se fait complice du VIH-1 pour détruire les défenses cellulaires. Med Sci (Paris) 2012; 28 : 356–358. [CrossRef] [EDP Sciences] [PubMed]
  42. Lahouassa H, Dragin L, Transy C, et al. SAMHD1 prive le VIH des nucléotides essentiels à la synthèse d’ADN viral. Med Sci (Paris) 2012 ; 28 : 909–910. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.